[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336881-105":59,"doc-detail-336881-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","alternative-splicing-in-ovarian-cancer","Alternative splicing in ovarian cancer","","Ovarian cancer remains highly lethal due to late detection and limited treatment effectiveness, with advanced-stage progression driving most deaths and keeping 5-year survival below 50% because of recurrence and chemoresistance. Alternative splicing, a core post-transcriptional regulatory mechanism, increases genomic complexity and protein diversity. This review links altered spliceosome machinery and splicing factors to ovarian cancer, summarizes variant effects on tumorigenesis and drug resistance, and integrates TCGA RNA-seq with clinical data to build prognostic models. Novel splicing events and therapeutic strategies, including splice-factor knockdown and bevacizumab, are highlighted.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/alternative-splicing-in-ovarian-cancer/336881/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/alternative-splicing-in-ovarian-cancer/336881.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is early detection of ovarian cancer difficult, and how does that affect survival?","Question",{"text":112,"@type":113},"Most ovarian cancer cases are diagnosed at an advanced stage because the disease is elusive and progresses rapidly, leading to a low overall 5-year survival rate.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does alternative splicing play in ovarian cancer?",{"text":117,"@type":113},"Alternative splicing is presented as a fundamental post-transcriptional regulation mechanism that increases genomic complexity and protein diversity, contributing to processes such as proliferation, metastasis, apoptosis, immune evasion, and chemoresistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How are prognostic models developed and what do they reveal?",{"text":121,"@type":113},"The review describes integrating TCGA RNA-seq data with clinical information to build prognostic models, which provide insights into splicing-related prognosis, overall survival, immune microenvironment features, and drug sensitivity or resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336881,1790141788,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Wei et al. Cell Communication and Signaling (2024) 22:507  \n[https://doi.org/10.1186/s12964-024-01880-8](https://doi.org/10.1186/s12964-024-01880-8)  \nCell Communication and Signaling  \nREVIEW Open Access  \nAlternative splicing in ovarian cancer  \nLiwei Wei 1,3†, Yisheng Li2,3†, Jiawang Chen4, Yuanmei Wang3,5, Jianmin Wu3,6, Huanming Yang3* andYi Zhang3,6*  \nAbstract  \nOvarian cancer is the second leading cause of gynecologic cancer death worldwide, with only 20% of cases detected early due to its elusive nature, limiting successful treatment. Most deaths occur from the disease progressing to advanced stages. Despite advances in chemo-and immunotherapy, the 5-year survival remains below 50% due to high recurrence and chemoresistance. Therefore, leveraging new research perspectives to understand molecular signatures and identify novel therapeutic targets is crucial for improving the clinical outcomes of ovarian cancer. Alternative splicing, a fundamental mechanism of post-transcriptional gene regulation, significantly contributes to heightened genomic complexity and protein diversity. Increased awareness has emerged about the multifaceted roles of alternative splicing in ovarian cancer, including cell proliferation, metastasis, apoptosis, immune evasion, and chemoresistance. We begin with an overview of altered splicing machinery, highlighting increased expression of spliceosome components and associated splicing factors like BUD31, SF3B4, and CTNNBL1, and their relationships to ovarian cancer. Next, we summarize the impact of specific variants of CD44, ECM1, and KAI1 on tumorigenesis and drug resistance through diverse mechanisms. Recent genomic and bioinformatics advances have enhanced our understanding. By incorporating data from The Cancer Genome Atlas RNA-seq, along with clinical information, a series of prognostic models have been developed, which provided deeper insights into how the splicing influences prognosis, overall survival, the immune microenvironment, and drug sensitivity and resistance in ovarian cancer patients. Notably, novel splicing events, such as PIGV|1299|AP and FLT3LG|50,941|AP, have been identified in multiple prognostic models and are associated with poorer and improved prognosis, respectively. These novel splicing variants warrant further functional characterization to unlock the underlying molecular mechanisms. Additionally, experimental evidence has underscored the potential therapeutic utility of targeting alternative splicing events, exemplified by the observation that knockdown of splicing factor BUD31 or antisense oligonucleotide-induced BCL2L12 exon skipping promotes apoptosis of ovarian cancer cells. In clinical settings, bevacizumab, a humanized monoclonal antibody that specifically targets the VEGF-A isoform, has demonstrated beneficial effects in the treatment of patients with advanced epithelial ovarian cancer. In conclusion, this review constitutes the first comprehensive and detailed exposition of the intricate interplay between alternative splicing and ovarian cancer, underscoring the significance of alternative splicing events as pivotal determinants in cancer biology and as promising avenues for future diagnostic and therapeutic intervention.  \n†Liwei Wei andYisheng Li contributed equally to this work.  \n*Correspondence: Huanming Yang [yanghm@genomics.cn](yanghm@genomics.cn)[ ](yanghm@genomics.cn)Yi Zhang [yizhang@wmu.edu.cn](yizhang@wmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this l","cbCaiaEIjRDhnyzB","https://ap.wps.com/l/cbCaiaEIjRDhnyzB","pdf",3154398,"English","# Abstract\n## Introduction","[{\"question\":\"Why is early detection of ovarian cancer difficult, and how does that affect survival?\",\"answer\":\"Most ovarian cancer cases are diagnosed at an advanced stage because the disease is elusive and progresses rapidly, leading to a low overall 5-year survival rate.\"},{\"question\":\"What role does alternative splicing play in ovarian cancer?\",\"answer\":\"Alternative splicing is presented as a fundamental post-transcriptional regulation mechanism that increases genomic complexity and protein diversity, contributing to processes such as proliferation, metastasis, apoptosis, immune evasion, and chemoresistance.\"},{\"question\":\"How are prognostic models developed and what do they reveal?\",\"answer\":\"The review describes integrating TCGA RNA-seq data with clinical information to build prognostic models, which provide insights into splicing-related prognosis, overall survival, immune microenvironment features, and drug sensitivity or resistance.\"}]","Alternative splicing in ovarian cancer | PDF",1790016945]